Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
July 30, 2013 -- China's State Intellectual Property Office (SIPO) has invalidated the patent for Viread, a treatment for hepatitis B and HIV/AIDS developed by Gilead Sciences. SIPO agreed with Aurisco, a China API maker, that Viread was not a novel drug because its active ingredient was discovered in the Czech Republic in 1985. Gilead had already lost patent protection for the drug in India and Brazil. Earlier this year, Gilead made an undisclosed settlement with Teva Pharma to end its challenge to Viread's US patent. More details....
Stock Symbols: (NSDQ: GILD) (NYSE: TEVA)
Help employers find you! Check out all the jobs and post your resume.
by Richard Daverman, PhD
July 30, 2013 -- China's State Intellectual Property Office (SIPO) has invalidated the patent for Viread, a treatment for hepatitis B and HIV/AIDS developed by Gilead Sciences. SIPO agreed with Aurisco, a China API maker, that Viread was not a novel drug because its active ingredient was discovered in the Czech Republic in 1985. Gilead had already lost patent protection for the drug in India and Brazil. Earlier this year, Gilead made an undisclosed settlement with Teva Pharma to end its challenge to Viread's US patent. More details....
Stock Symbols: (NSDQ: GILD) (NYSE: TEVA)
Help employers find you! Check out all the jobs and post your resume.
